semaglutide cv outcomes cardiovascular align more closely with attained dose than achieved weight loss SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Description
Semaglutide 5mg: Selective GLP-1 Receptor Agonist Research Compound
The Food and Drug Administration's approval of a Wegovy pill, the first ever oral GLP-1 medication on Dec
Research shows semaglutide can support weight loss in older adults, though efficacy and tolerability vary by individual health status, medication interactions, and metabolic factors
Retatrutide: An investigational triple agonist (GIP, GLP-1, glucagon) studied for metabolic outcomes
